FindTrial
Sign In

Clinical study of biomarker combination for early diagnosis and efficacy evaluation of acute graft versus host disease

Clinical study of biomarker combination for early diagnosis and efficacy evaluation of acute graft versus host disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040664
Enrollment
Unknown
Registered
2020-12-07
Start date
2020-12-07
Completion date
Unknown
Last updated
2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graft Versus Host Disease

Interventions

Gold Standard:Clinical outcome
Index test:TLR4,&#32
TNF&#32
R1,&#32
Elafin&#32
and&#32
TGF-beta&#32
mixture&#32
kit

Sponsors

Medical Center of Hematology, Xinqiao Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 60 years old men and women; 2. After allogeneic hematopoietic stem cell transplantation, the underlying disease was stable, no progress, no recurrence; 3. No active or chronic infection.

Exclusion criteria

Exclusion criteria: Patients were excluded if they had ongoing or active infection, Severe cardiac disease, or active malignancy, inability to schedule follow-up, brain dysfunction or severe mental illness preventing compliance with the study protocol.

Design outcomes

Primary

MeasureTime frame
To detect the expression levels of four biomarkers;—

Secondary

MeasureTime frame
The severity of aGVHD;Steroid Refractory aGVHD;—

Countries

China

Contacts

Public ContactChen Ting

Medical Center of Hematology, Xinqiao Hospital of Army Medical University

747640395@qq.com+86 13637920152

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026